Fig. 2
From: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
Comparison of the effect of sotagliflozin on HbA1c (a) and fasting plasma glucose (b) in various clinical trials on type 2 diabetic patients
Advertisement
Fig. 2 | Cardiovascular Diabetology
